Kronenberg F, Kathrein H, König P, Neyer U, Sturm W, Lhotta K, Gröchenig E, Utermann G, Dieplinger H
Institute of Medical Biology and Human Genetics, Innsbruck, Austria.
Arterioscler Thromb. 1994 Sep;14(9):1405-11. doi: 10.1161/01.atv.14.9.1405.
Several studies have demonstrated that atherosclerotic complications are the major cause of morbidity and mortality in hemodialysis patients. High lipoprotein(a) [Lp(a)] plasma concentrations are an independent risk factor for atherosclerosis. Patients with end-stage renal disease (ESRD) have elevated plasma concentrations of Lp(a), which are not explained by size variation at the apolipoprotein(a) [apo(a)] gene locus. The aim of our study was to investigate whether Lp(a) concentrations and/or apo(a) phenotypes are predictive of the degree of atherosclerosis in the extracranial carotid arteries in ESRD patients. Of 167 patients, 108 showed atherosclerotic plaques (65%). Univariate analysis showed that the plaque-affected group was significantly older and had a higher frequency of angina pectoris, previous myocardial infarction, or cerebrovascular accident. Furthermore, this group included significantly more patients with low-molecular-weight apo(a) isoforms (26.9% versus 8.5%, P < .005) and had significantly higher mean Lp(a) plasma concentrations (29.3 +/- 31.0 versus 19.7 +/- 25.7 mg/dL, P < .05). Lp(a) plasma concentration increased significantly with the number of affected arterial sites, from 19.7 mg/dL in patients without plaques to 40.1 mg/dL in patients with seven or eight affected sites. In patients with low-molecular-weight phenotypes, significantly more arterial sites were affected (3.62 versus 2.08, P < .001). Multivariate regression analysis showed that age, angina pectoris, and the apo(a) phenotype were the only significant predictors of the degree of atherosclerosis. We conclude that, besides age, the apo(a) phenotype is the best predictor of carotid atherosclerosis in ESRD patients and may be used for assessment of general atherosclerosis risk in this patient group.
多项研究表明,动脉粥样硬化并发症是血液透析患者发病和死亡的主要原因。高脂蛋白(a)[Lp(a)]血浆浓度是动脉粥样硬化的独立危险因素。终末期肾病(ESRD)患者的血浆Lp(a)浓度升高,这不能用载脂蛋白(a)[apo(a)]基因位点的大小变异来解释。我们研究的目的是调查Lp(a)浓度和/或apo(a)表型是否可预测ESRD患者颅外颈动脉的动脉粥样硬化程度。在167例患者中,108例显示有动脉粥样硬化斑块(65%)。单因素分析显示,斑块受累组年龄显著更大,心绞痛、既往心肌梗死或脑血管意外的发生率更高。此外,该组中低分子量apo(a)异构体的患者明显更多(26.9%对8.5%,P<0.005),且平均血浆Lp(a)浓度显著更高(29.3±31.0对19.7±25.7mg/dL,P<0.05)。血浆Lp(a)浓度随受累动脉部位数量的增加而显著升高,从无斑块患者的19.7mg/dL增加到有7个或8个受累部位患者的40.1mg/dL。在低分子量表型的患者中,受累动脉部位明显更多(3.62对2.08,P<0.001)。多因素回归分析显示,年龄、心绞痛和apo(a)表型是动脉粥样硬化程度的唯一显著预测因素。我们得出结论,除年龄外,apo(a)表型是ESRD患者颈动脉粥样硬化的最佳预测因素,可用于评估该患者群体的总体动脉粥样硬化风险。